## What is claimed is:

- 1. A method of treating or inhibiting hepatic fibrosis in a mammal in need thereof, which comprises providing to said mammal an effective amount of a CCI-779.
- 2. The method according to claim 1, wherein CCI-779 is provided to said mammal by oral or intravenous infusion.
- 3. The method according to claim 1, wherein CCI-779 provided to said mammal by administration of a prodrug, derivative, pharmaceutical salt or analog of CCI-779 that forms an effective amount of CCI-779 in the body.
- 4. The method according to claim 1, wherein CCI-779 is administered by direct targeting to the liver.
- 5. The method according to claim 1, wherein CCI-779 is provided to said mammal by oral dose.
- 6. A method of treating or inhibiting hepatic cirrhosis in a mammal in need thereof, which comprises providing to said mammal an effective amount of a CCI-779.
- 7. The method according to claim 6, wherein CCI-779 is provided to said mammal by oral or intravenous infusion.
- 8. The method according to claim 6, wherein CCI-779 provided to said mammal by administration of a prodrug, derivative, pharmaceutical salt or analog of CCI-779 that forms an effective amount of CCI-779 in the body.
- 9. The method according to claim 6, wherein CCI-779 is administered by direct targeting to the liver.

10. The method according to claim 1, wherein CCI-779 is provided to said mammal by oral dose.